The hazards of intermediate endpoints

Cancer

Volumn 110, Issue 9, 2007, Pages 1877-1879

  Beer, Tomasz M ^a,b   Ryan, Christopher W ^a  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATRASENTAN; PLACEBO; PREDNISONE; PROSTATE SPECIFIC ANTIGEN; SATRAPLATIN;

ADVANCED CANCER; BONE METASTASIS; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DISEASE FREE SURVIVAL; EDITORIAL; HUMAN; IMAGING SYSTEM; LABORATORY TEST; MALE; MONOTHERAPY; OUTCOMES RESEARCH; PATIENT MONITORING; PRIORITY JOURNAL; PROSTATE CANCER; TREATMENT OUTCOME;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE-FREE SURVIVAL; ENDPOINT DETERMINATION; HUMANS; MALE; PROSTATIC NEOPLASMS;

EID: 35648997506     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.22995     Document Type: Editorial

References (9)

1. Carcuddi MA, Saad F, Abrahamsson P-A, et al. A phase 3 randomized controlled trial of the efficacy and safety of atrasentan in men with metastatic hormone-refractory prostate cancer. Cancer. 2007:110:1959-1966.
2. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol. 2003;21:679-689.
3. Petrylak DP, Ankerst DP, Jiang CS, et al. Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16. J Natl Cancer Inst. 2006;98:516-521.
4. Scher HI, Warren M, Heller G. The association between measures of progression and survival in castrate-metastatic prostate cancer. Clin Cancer Res. 2007;13:1488-1492.
5. Thompson IM. Flare associated with LHRH-agonist therapy. Rev Urol. 2001;3(suppl 3):S10-S14.
6. Olbert PJ, Hegele A, Kraeuter P, Heidenreich A, Hofmann R, Schrader AJ. Clinical significance of a prostate-specific antigen flare phenomenon in patients with hormone-refractory prostate cancer receiving docetaxel. Anticancer Drugs. 2006;17:993-996.
7. Moertel CG, Hanley JA. The effect of measuring error on the results of therapeutic trials in advanced cancer. Cancer. 1976;38:388-394.
8. Scher HI, Halabi S, Tannock I, et al. The Prostate Cancer Clinical Trials Working Group (PCCTWG) consensus for phase II trials in metastatic castration-resistant prostate cancer. Proceedings of the 2007 ASCO Prostate Cancer Symposium, Orlando, Florida, February 22-24, 2007. Abstract 182.
9. Petrylak DP, Sartor O, Witjes F, et al. A phase III, randomized, double-blind trial of satraplatin and prednisone vs placebo and prednisone for patients with hormone refractory prostate cancer (HRPC). Proceedings of the 2007 ASCO Prostate Cancer Symposium, Orlando, Florida, February 22-24, 2007. Abstract 144.